There was no significant difference between subjects who switched ER, PR, and/or HER2 status and the number and type of previous treatments (including endocrine treatments) for breast cancer, the time between diagnosis and recurrence, the tumor size, grade of tumor, node status, or the Nottingham Prognostic Index derived from the primary cancer. The gene discussed is ERBB2; the disease is cancer.